Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

NCT ID: NCT03756558

Last Updated: 2025-09-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 147 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-09
• Study Completion Date: 2021-03-22

Brief Summary

This study evaluates the safety and effectiveness of the Cross-Seal vascular closure device in gaining post procedure hemostasis in subjects undergoing interventional procedures requiring an 8 to 18 french size introducer sheath.

Detailed Description

The Cross-Seal device is a VCD intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (8-18F ID) interventional devices. The function of Cross-Seal is to percutaneously close the puncture in the artery wall (arteriotomy) through which the catheters were inserted for the procedure.

The study is being conducted to demonstrate the safety and effectiveness of Cross-Seal in achieving hemostasis in femoral arterial access sites in subjects undergoing percutaneous transcatheter interventional procedures using a large-bore procedure sheath.

Conditions

Vascular Closure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cross-Seal System

The Cross-Seal System will be used in all subjects enrolled in the study

Group Type: EXPERIMENTAL

Cross-Seal System

Intervention Type: DEVICE

Use of the Cross-Seal system to close the femoral arteriotomy

Interventions

Cross-Seal System

Use of the Cross-Seal system to close the femoral arteriotomy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject is ≥ 18 years old

2. Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-18 French introducer sheaths

3. Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery

4. Subject is willing and able to complete follow-up requirements

5. Subject, or authorized representative signs a written Informed Consent form prior participating in the study

Exclusion Criteria

1. Prior intra-aortic balloon pump at access site

2. Subjects with severe inflow disease (iliac artery diameter stenosis > 50%) and/or severe peripheral arterial disease (Rutherford Classification 5 or 6), as confirmed with prior standard of care Computed Tomography Imaging, duplex ultrasound, and/or intra-procedural fluoroscopy

3. Common femoral artery lumen diameter is < 5 mm

4. In opinion of the investigator, significant scarring of the target access site which would preclude use of the device in accordance with the IFU

5. Prior target artery closure with any closure device < 90 days, or closure with manual compression ≤ 30 days prior to index procedure

6. Prior vascular surgery, vascular graft, or stent in region of access site

7. Subjects receiving glycoprotein IIb/IIIa inhibitors before, during, or after the catheterization procedure

8. Subjects with significant anemia

9. Subject with known bleeding disorder including thrombocytopenia (platelet count < 100,000), thrombasthenia, hemophilia or Von Willebrand's disease

10. Subject with renal insufficiency, on dialysis therapy, or with renal transplant

11. Known severe allergy to contrast reagent that cannot be managed with premedication

12. Inability to tolerate aspirin and/or other anticoagulation/antiplatelet treatment

13. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure

14. Connective tissue disease (e.g., Marfan's Syndrome)

15. Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure

16. Recent (within 8 weeks) cerebrovascular accident or Q-wave myocardial infarction

17. Subjects who are morbidly obese

18. Planned major intervention or surgery, including planned endovascular procedure in the target leg, within 30 days following the interventional procedure

19. Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed)

20. Currently participating in a clinical study of an investigational device or drug that has not completed its primary study endpoint

21. Known allergy to any device component

22. Subject is known or suspected to be pregnant or lactating

23. Evidence of active systemic or local groin infection

24. Subject has other medical, social or psychological problem that in the opinion of the investigator precludes them from participating

25. Subject is mentally incompetent or a prisoner

26. New York Heart Association (NYHA) Class IV heart failure that is uncontrolled and requires treatment in the Intensive Care Unit within 24 hours prior to the index procedure

27. Left Ventricular Ejection Fraction (LVEF) < 20%

28. Unilateral or bilateral lower extremity amputation

29. Known existing nerve damage in the target leg

30. Subjects who have already participated in this study

31. Access site above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks

32. Access site in the profunda femoris or superficial femoral arteries, or the bifurcation of these vessels

33. Ipsilateral femoral venous sheath during the catheterization procedure

34. Common femoral artery calcium, which is visible with prior Computed Tomography Imaging and/or duplex ultrasound

35. Subject in which there is difficulty inserting the introducer sheath or need for greater than 2 ipsilateral arterial punctures at the start of the catheterization procedure

36. Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture

37. Evidence of a pre-existing hematoma (> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site

38. Marked tortuosity (at the investigator's discretion) of the femoral or external iliac artery in the target leg based on prior Computed Tomography imaging, fluoroscopy, and/or duplex ultrasound

39. Angiographic evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the investigational device

40. Target arteriotomy >18 French sheath

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Terumo Medical Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mazin Foteh, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiothoracic and Vascular Surgeons - Austin

Prakash Krishnan

Role: PRINCIPAL_INVESTIGATOR

Icahan School of Medicine at Mt Sinai

Locations

Vascular Institute of the Rockies

Denver, Colorado, United States

River City Clinical Research

Jacksonville, Florida, United States

University of South Florida

Tampa, Florida, United States

University of Iowa Hospital

Iowa City, Iowa, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Rutgers, The State University of New Jersey

Piscataway, New Jersey, United States

Mt Sinai Medical Center

New York, New York, United States

The Trustees of Columbia University in the City of New York

New York, New York, United States

University of Rochester

Rochester, New York, United States

Good Samaritan Hospital

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

INTEGRIS Cardiovascular Physicians

Oklahoma City, Oklahoma, United States

Lankenau Institute for Medical Research

Wynnewood, Pennsylvania, United States

North Central Heart

Sioux Falls, South Dakota, United States

Holston Valley Medical Center

Kingsport, Tennessee, United States

Cardiothoracic and Vascular Surgeons

Austin, Texas, United States

St. David's Heart and Vascular dba Austin heart

Austin, Texas, United States

Texas Heart Institute and Baylor St. Luke's Medical Center

Houston, Texas, United States

Sentara Medical Group

Norfolk, Virginia, United States

Swedish Medical Center

Seattle, Washington, United States

Countries

United States

References

Krishnan P, Farhan S, Zidar F, Krajcer Z, Metzger C, Kapadia S, Moore E, Nazif T, Garland T, Zhang M, Khera S, Sharafuddin M, Patel VI, Bacharach JM, Coady P, Schermerhorn ML, Shames ML, Rahimi S, Panneton JM, Elkins C, Foteh M. Cross-Seal IDE Trial: Prospective, Multicenter, Single-Arm Study of the Cross-Seal Suture-Mediated Vascular Closure Device System. Circ Cardiovasc Interv. 2024 Jun;17(6):e013842. doi: 10.1161/CIRCINTERVENTIONS.123.013842. Epub 2024 May 6.

Reference Type: DERIVED

PMID: 38708595 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

TIS2018-01

Identifier Type: -

Identifier Source: org_study_id